TUDCA

TUDCA (tauroursodeoxycholic acid) is a water-soluble bile acid your body already makes in small amounts. Most people take it as a liver protector during anything that taxes the liver, oral steroid cycles, heavy drinking phases, long courses of hepatotoxic medications, or just chronically elevated ALT/AST on bloodwork. It's the supplement you reach for when you know you're putting your liver through something and you want to soften the damage.

It works by improving bile flow, swapping out the more toxic bile acids in your bile pool for milder ones, and calming the cellular stress response inside liver cells that drives them to die when they're overloaded. In humans, it consistently lowers ALT, AST, GGT, and ALP, the markers most people are actually watching. Beyond the liver, it shows up in research on insulin sensitivity, neurodegenerative disease, and gut health, but the liver story is where the evidence is strongest and where most people benefit.

Deep-dive

TUDCA is the taurine-conjugated form of UDCA (ursodeoxycholic acid). Your gut bacteria already convert a small amount of UDCA into TUDCA naturally, and your liver does the rest by conjugating taurine onto UDCA. Bear bile is the richest natural source, which is why it's been used in traditional Chinese medicine for over 3,000 years for liver and eye complaints.

How it actually protects the liver. TUDCA works through three overlapping mechanisms. First, it's hydrophilic where most native bile acids are hydrophobic, so when it enters the bile pool it dilutes the membrane-damaging effect of harsher bile acids on hepatocytes. Second, it acts as a chemical chaperone inside cells, helping misfolded proteins fold correctly and reducing endoplasmic reticulum (ER) stress, the cellular alarm state that, when sustained, triggers apoptosis. Third, it directly inhibits the mitochondrial apoptosis pathway, blocking cytochrome c release and downstream caspase activation. The net effect is that hepatocytes under chemical, metabolic, or cholestatic stress stay alive longer and function better. A 2017 mouse model of biliary fibrosis found TUDCA at 10 mg/kg/day reduced fibrosis significantly alongside lower CHOP and caspase expression, the molecular signature of the ER-stress-to-apoptosis pathway being shut down.

Liver enzymes in humans. A 6-month randomised trial in cirrhosis patients compared TUDCA at 750 mg/day to UDCA at the same dose. The TUDCA group showed significant reductions in ALT, AST, and ALP from baseline. The UDCA group only saw AST drop. Both groups raised serum albumin. Both were well tolerated. In primary biliary cholangitis, a 2-month trial in 12 women reported a roughly 51% drop in liver enzymes on TUDCA. The pattern is consistent across the cholestatic and inflammatory liver literature: ALT, AST, GGT, and ALP fall, usually within 1-3 months.

Insulin sensitivity. A 2010 randomised trial in 20 obese, insulin-resistant adults gave 1,750 mg/day of TUDCA or placebo for 4 weeks. The TUDCA group showed roughly 30% improvements in liver and muscle insulin sensitivity, with no change in adipose tissue. Muscle insulin signalling (phosphorylated IRS and Akt) improved measurably. The proposed mechanism is the same chemical-chaperone effect, the ER in obese livers and muscle is chronically stressed, and TUDCA quiets it. Interestingly, ER stress markers in the biopsied tissue didn't change much, which leaves the exact pathway open. It's a small, short trial, and it hasn't been replicated at scale, but the signal is real.

Neurodegeneration. TUDCA crosses the blood-brain barrier, which is unusual for a bile acid. Animal models of Alzheimer's, Parkinson's, Huntington's, and ALS consistently show TUDCA reducing apoptosis, oxidative stress, and protein aggregation in neurons. The clinical translation has been mixed. A 2016 phase II trial in 34 ALS patients gave 1 g twice daily for 54 weeks on top of riluzole and found significantly slower functional decline (ALSFRS-R) in the TUDCA arm. A Cox regression follow-up suggested a survival benefit. However, the phase III TUDCA-ALS trial, which read out in 2024 in 334 patients across Europe, did not meet its primary endpoint, no significant slowing of ALSFRS-R decline at 18 months, and no survival benefit. That's a real setback for the neurodegeneration story. The mechanism still looks plausible in cells and rodents, but in humans with established ALS the effect didn't hold up. For Alzheimer's and Parkinson's, no positive human trials yet.

Gallstones. TUDCA can dissolve cholesterol gallstones, the same way UDCA does, by shifting the bile pool toward unsaturation. It's a slow process (months) and only works on cholesterol stones (not pigment stones) in patients with a functioning gallbladder. The clinical use case is narrow: transient gallstone formers (pregnancy, rapid weight loss, post-bariatric) where surgery is undesirable.

Women. The cholestasis and primary biliary cholangitis literature is heavily female (PBC is about 90% women), so most of the strongest liver enzyme data is in women. The cirrhosis and insulin sensitivity trials included both sexes with similar effects. No dose adjustment needed. Women on the oral contraceptive pill, in pregnancy, or in perimenopause have a higher background risk of cholestasis and gallstones, and TUDCA is mechanistically suited to all three, though pregnancy is a special case (UDCA, not TUDCA, is the standard of care for intrahepatic cholestasis of pregnancy, with a stronger safety record). Oral oestrogen raises hepatic cholesterol output and slows gallbladder motility, so women on it who have elevated ALT or upper-right-quadrant symptoms are a real candidate population.

Older adults. No specific dose adjustments needed, but older livers metabolise more slowly and bile flow naturally declines with age. The same dose works, the effect may feel more noticeable in someone with subclinical sluggish bile flow.

Limitations of the evidence. Most human trials are small, short (under 6 months), and run in specific disease populations (PBC, cirrhosis, ALS, obesity). There is essentially no long-term safety or efficacy data past about a year in healthy people. The bodybuilding-cycle use case, take TUDCA alongside an oral 17α-alkylated steroid to protect the liver, is supported by mechanism and by enzyme-lowering data in unrelated liver conditions, but there is no head-to-head trial of TUDCA versus placebo in people on oral anabolics. It's a reasonable bet, not a proven intervention.

Dosage:

General liver support / mildly elevated enzymes: 250-500 mg/day. Take with food. Enough for most people who just want background protection or are on something mildly hepatotoxic

Oral steroid cycles (17α-alkylated compounds like Anadrol, Superdrol, Dianabol, Anavar, Halotestin): 500-1000 mg/day, split into two doses, run for the duration of the cycle and 2-4 weeks after. Higher end (1000-1500 mg) for harsher compounds or stacked orals

Active cholestasis or significantly elevated ALT/AST (2-3x upper limit and above): 750-1500 mg/day in 2-3 divided doses. This is the dose range that mirrors the cirrhosis and PBC trials. If enzymes don't come down in 8-12 weeks, get a proper workup, supplements aren't a substitute for a diagnosis

Insulin sensitivity / metabolic use: 1500-1750 mg/day, the dose used in the only positive human trial. Expensive and the evidence is thin outside that one study, most people are better served by training and diet for this purpose

Timing: With meals improves tolerability, particularly the larger doses, since bile is naturally released with food. Some people split doses morning and evening to keep bile flow steady

Stacking: Pairs well with NAC (600-1200 mg/day) for anyone on oral anabolics or otherwise loading the liver, the mechanisms are complementary (NAC supports glutathione, TUDCA handles bile acid pool and ER stress). Milk thistle is commonly stacked but the evidence is weaker. Don't stack TUDCA with cholestyramine or other bile acid sequestrants, they'll bind it before it works

Cycling: Continuous use up to 6-12 months has been studied without serious issues. Beyond that, data thins out. Most people use it situationally (during a cycle, during a heavy drinking period, while on a hepatotoxic medication) rather than daily for life

Here's what you can expect:

For liver protection during a cycle or other hepatotoxic period, you won't feel anything subjectively. The point is what doesn't happen, you don't see ALT/AST climb the way they would otherwise, you don't get the upper-right-quadrant discomfort, dark urine, or itching that signals cholestasis kicking in. The benefit is visible on bloodwork, not in how you feel.

For people starting with already-elevated enzymes (fatty liver, post-cycle, recovering from alcohol, drug-induced), expect a measurable drop in ALT, AST, GGT, and ALP within 4-12 weeks at 750-1500 mg/day. The drop tends to be in the 30-50% range from baseline in the studied populations.

Some people report improved digestion of fats and reduced bloating after fatty meals, particularly those with sluggish bile flow, gallbladder removal, or low stomach acid. This is plausible mechanistically and shows up frequently in anecdotal reports, but isn't directly tested in trials.

Don't expect to feel sharper, more energetic, or different in mood. TUDCA isn't doing anything in the brain you'll notice. The neurodegeneration data is about slowing decline in disease, not enhancing cognition in healthy people.

Side effects & risks:

Diarrhoea and loose stools are the most consistently reported side effect across trials, dose-dependent, usually mild, often resolves by splitting the dose or taking with food. This is the only side effect reported in the Cochrane meta-analysis of bile acid trials in liver transplant patients

GI discomfort (nausea, bloating, mild cramping) particularly at higher doses (1500 mg+). Usually transient

Bile acid sequestrant interaction: cholestyramine, colestipol, and colesevelam bind TUDCA in the gut and prevent absorption. Space them by at least 4 hours, or pick one

Aluminium-containing antacids also bind bile acids and reduce absorption. Same spacing rule

Bile duct obstruction is a hard contraindication. TUDCA increases bile flow. In a blocked duct, that increased flow has nowhere to go and worsens the situation. Confirm patent biliary anatomy before using TUDCA in anyone with a history of stones, biliary surgery, or suspicious symptoms

Pigment gallstones won't dissolve and TUDCA isn't useful for them. Cholesterol stones can dissolve over months but stones over 1.5 cm or calcified stones are unlikely to respond

Pregnancy: UDCA (not TUDCA) is the established treatment for intrahepatic cholestasis of pregnancy, with FDA category B safety data. TUDCA has very limited direct pregnancy safety data. If pregnancy-related cholestasis is the issue, use UDCA under medical supervision

Active gastrointestinal bleeding or severe peptic ulcer disease: caution, bile acid supplementation can aggravate

TUDCA is not a license to abuse oral steroids. It blunts enzyme elevations but does not eliminate the underlying hepatocyte damage. People on harsh orals at high doses with normal ALT/AST on TUDCA can still have meaningful liver damage. Cholestasis in particular can present with near-normal ALT/AST and significantly elevated bilirubin. Track bilirubin, GGT, and ALP, not just ALT/AST

Long-term safety beyond 12 months in healthy people is unknown. The longest controlled trials run about a year. Indefinite daily use isn't supported by data either way

🩸

Blood markers

ALT, AST, GGT, ALP, total bilirubin, direct bilirubin — full liver panel at baseline. These are the markers TUDCA actually moves and the ones that tell you whether it's working. GGT and ALP catch cholestatic patterns that ALT/AST miss. Recheck at 4-12 weeks if you're using it for active liver stress (on cycle, post-cycle, elevated baseline enzymes).

Total bilirubin specifically — cholestasis from oral anabolics can present with near-normal ALT/AST but bilirubin climbing. Don't skip it, particularly on cycle.

Fasting glucose, fasting insulin, HbA1c — baseline if you're using TUDCA for metabolic/insulin sensitivity purposes (1500+ mg). Recheck at 3 months. Otherwise not needed.

Lipid panel — baseline for anyone on oral anabolics. TUDCA itself is neutral on lipids but oral steroids tank HDL, and you want a reference point.

Ultrasound or imaging — not blood, but worth flagging. If you have a personal or family history of gallstones, get an abdominal ultrasound before starting TUDCA at higher doses. Rules out bile duct obstruction, which is the one genuine hard contraindication.

For most people using TUDCA at 250-500 mg/day for general support, a basic liver panel (ALT, AST, GGT, ALP, bilirubin) at baseline and once a year is sufficient.

Sold as a dietary supplement in most countries and as a prescription drug for cholestatic liver disease in others (notably Italy and parts of Asia).